
UnitedHealth Stock Collapse Continues: Here's What This Investor Thinks Will Happen Next
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Since the assassination of Brian Thompson, the CEO of its insurance division, in New York last year, the company has faced mounting scrutiny. Investors are increasingly uneasy about UnitedHealth's transparency, while the public has raised sharp concerns over its claims-handling practices.
Given the reputational setbacks, investor A.J. Button believes the fallout could soon weigh on the company's bottom line.
'Bad PR can lead to brand damage,' he warns, 'which in turn can lead to policyholders taking their business elsewhere.'
That said, Button acknowledges that the company's fundamentals remain relatively strong. UNH still boasts a robust balance sheet and solid profitability metrics, suggesting it has the financial strength to withstand pressure. 'Nevertheless,' Button cautions, 'the issues facing UnitedHealth right now are very real.'
One of the most pressing red flags is the company's exceptionally high claim denial rate, reportedly the highest in the sector, according to multiple sources. While not catastrophic in itself, such a pattern could indicate flawed underwriting or strained claims infrastructure – issues that compound the reputational damage and hint at possible internal mismanagement.
'So,' Button adds, 'UnitedHealth has many qualities, good and bad.' On one hand, its financial footing and history of profitability provide a cushion. On the other, cracks are beginning to show: for fiscal 2024, its combined ratio hit 97.2% – right up against the industry's red line. Button argues that, before investors can have full confidence, the company needs to take meaningful action to shore up its underwriting performance.
Whether that turnaround is underway remains an open question. UnitedHealth recently reinstated former CEO Stephen Helmsley, following the previous leader's departure. But the move has raised eyebrows, given that Helmsley is a longtime insider who presided over many of the company's earlier challenges. His return doesn't exactly scream transformation.
A rebound is still possible – especially if the company takes decisive steps to restore trust and address internal inefficiencies. However, given the scale of its current controversies, Button advises investors to weigh the risks carefully. Even the stock's seemingly low P/E ratio doesn't present a compelling bargain relative to peers in the life and health insurance space.
'When considering a stock like UnitedHealth, with a good track record but an unprecedented new set of risk factors, it pays to be cautious,' the investor summed up.
Can UnitedHealth Stock Bounce Back?
Button assigns a 'low-conviction' buy rating on UNH shares – a nod to its potential, but with more than a few strings attached. (To watch Button's track record, click here)
Wall Street, though, is a bit more upbeat. The stock holds 19 Buy recommendations, 6 Holds, and just 1 Sell, translating to a Moderate Buy consensus rating. With an average price target of $364.96, analysts are eyeing 29% upside from current levels. (See UNH stock forecast)
To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Phillips 66 (PSX) Q2 2025 Earnings Call Highlights: Record Refining Utilization and Strong ...
Refining Utilization: 98% utilization, highest since 2018. Clean Product Yield: Over 86% yield. Midstream Adjusted EBITDA: Approximately $1 billion. Shareholder Returns: Over $900 million returned, including $490 million in share repurchases. Reported Earnings: $877 million or $2.15 per share. Adjusted Earnings: $973 million or $2.38 per share. Operating Cash Flow: $845 million; excluding working capital, $1.9 billion. Net Debt to Capital: 41%. Refining Market Capture: 99% of market indicator. Cash from Operations: $1.9 billion, excluding working capital. Capital Spending: $587 million. Ending Cash Balance: $1.1 billion. Warning! GuruFocus has detected 8 Warning Sign with PSX. Release Date: July 25, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Phillips 66 (NYSE:PSX) achieved a refining utilization rate of 98%, the highest since 2018, and a clean product yield of over 86%. The Midstream segment generated an adjusted EBITDA of approximately $1 billion, on track to achieve the $4.5 billion annual EBITDA target by 2027. Marketing and Specialties reported its strongest quarter since 2022, contributing to a robust capital allocation framework. Phillips 66 (NYSE:PSX) returned over $900 million to shareholders this quarter, demonstrating strong shareholder returns. The company achieved the lowest adjusted refining cost per barrel since 2021, with plans to reduce it further by 2027. Negative Points The Chemicals segment saw decreased results due to lower polyethylene margins driven by lower sales prices. Phillips 66 (NYSE:PSX) reported a $239 million pre-tax impact of accelerated depreciation due to the planned cessation of operations at the Los Angeles refinery. Net debt to capital was 41%, reflecting the impact of the Coastal Bend asset acquisition, indicating a need to reduce debt levels. Renewable fuels margins were weak, leading to reduced operational rates at the Rodeo facility. The company faces regulatory challenges in the renewable fuels segment, including changes in eligible feedstocks for PTC credits. Q & A Highlights Q: After the recent shareholder engagement, are you still comfortable with the current strategy of Phillips 66 as an integrated company, or do you foresee any changes? A: Mark Lashier, Chairman and CEO, stated that the company remains committed to its current strategy, which has been supported by shareholder feedback. The board continuously evaluates strategic alternatives to ensure long-term shareholder value creation, and there are no sacred cows except for the focus on shareholder value. Q: Given the strong quarter, how does the current environment affect your $15 billion EBITDA target, and what is the right level of debt for the company? A: Mark Lashier explained that the refining EBITDA was $867 million for the quarter, which annualizes to $3.5 billion at an $11 market indicator. The company aims for a $14 market indicator as mid-cycle, which would bring refining EBITDA to over $5 billion. Kevin Mitchell, CFO, added that the target debt level is $17 billion, which they plan to achieve through cash flow and asset dispositions. Q: What drove the significant quarter-over-quarter improvement in refining results, achieving 99% market capture and 98% crude utilization? A: Rich Harbison, Executive Vice President of Refining, attributed the improvement to a focus on safe and reliable operations, comprehensive reliability programs, and small capital high-return projects that enhanced clean product yield and flexibility. The company also managed costs effectively, achieving a refining cost of $5.46 per barrel. Q: Can you provide insights into the global refining capacity additions and the impact of China's export capacity on the market? A: Brian Mandell, Executive Vice President of Marketing and Commercial, noted that net refinery additions are expected to be below demand expectations through the decade, with low clean product yields from new Asian refineries. This supports a strong margin environment, despite potential unplanned shutdowns and rationalizations in Europe and Asia. Q: How is Phillips 66 addressing the challenges in the renewable fuels segment, given the weak margins? A: Brian Mandell mentioned that the company is running its renewable diesel plant at reduced rates due to weak margins. They are working on lowering operating costs, increasing SAF production, and enhancing feedstock optionality. Regulatory changes and market dynamics are being closely monitored to ensure profitability. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 minutes ago
- Yahoo
Stellar Bancorp Inc (STEL) Q2 2025 Earnings Call Highlights: Strong Net Income Growth and ...
Net Income: $26.4 million or $0.51 per share, up from $24.7 million or $0.46 per share in Q1 2025. Annualized ROAA: 1.01% for Q2 2025. Annualized ROATCE: 12.16% for Q2 2025. Net Interest Income: $98.3 million, a slight decrease from $99.3 million in Q1 2025. Net Interest Margin: 4.18% in Q2 2025, down from 4.2% in Q1 2025. Purchase Accounting Accretion: $5.3 million in Q2 2025, relatively flat compared to $5.4 million in Q1 2025. Provision for Credit Losses: $1.1 million in Q2 2025. Allowance for Credit Losses on Loans: $83.2 million or 1.14% of loans, down from 1.15% in Q1 2025. Non-Interest Income: $5.8 million in Q2 2025, up from $5.5 million in Q1 2025. Non-Interest Expense: Approximately $70 million, essentially flat for the quarter. Total Risk-Based Capital: 15.98% at the end of Q2 2025, up slightly from 15.97% in Q1 2025. Tangible Book Value: Increased 10.8% year-over-year from $18 per share to $19.94 per share. Share Repurchases: 791,000 shares at a weighted average price of $26.08 per share during Q2 2025. Warning! GuruFocus has detected 7 Warning Sign with STEL. Release Date: July 25, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Stellar Bancorp Inc (NYSE:STEL) reported a net income increase to $26.4 million or $0.51 per share in Q2 2025, up from $24.7 million or $0.46 per share in Q1. New loan originations nearly doubled in the second quarter compared to the first, indicating a strong pipeline and potential for future growth. The company maintained a healthy net interest margin of 4.18% in Q2, despite a slight decrease from the previous quarter. Stellar Bancorp Inc (NYSE:STEL) experienced deposit growth, contributing to an incremental balance sheet increase. The company successfully managed non-interest expenses, keeping them flat at approximately $70 million, which was better than planned. Negative Points Net interest income slightly decreased to $98.3 million in Q2 from $99.3 million in Q1, due to lower earning assets and a slightly lower net interest margin. Higher funding costs offset higher yields on earning assets, impacting the margin performance during the second quarter. The allowance for credit losses on loans decreased slightly, ending the quarter at $83.2 million or 1.14% of loans, down from 1.15% in the previous quarter. The competitive landscape for funding remains challenging, particularly in the money market, affecting the strategy for driving core deposits. Despite a focus on expense management, the company remains cautious about potential opportunistic investments that could impact future expenses. Q & A Highlights Q: Can you discuss the competitive landscape for loan originations and when growth might accelerate? A: Ramon Vitulli, President and CEO of Stellar Bank, explained that loan originations nearly doubled in the second quarter compared to the first, supported by a healthy pipeline. The bank expects growth as originations exceed payoffs, driven by property trades. New hires are gaining traction, particularly in the Dallas and Houston-Beaumont regions. Q: What is the strategy for funding and core deposits, and how do you see funding costs evolving? A: Ramon Vitulli noted that while time deposits are less competitive, money markets remain competitive. The bank uses a measured approach with exception pricing. The second quarter saw strong net new deposits, with 50% from new customers, indicating a strategy to expand the customer base. Q: How is Stellar Bancorp managing expenses, and are there opportunities for investment in new talent? A: Paul Egge, CFO, stated that the bank is holding the line on expenses to remain opportunistic for future opportunities. CEO Robert Franklin added that while back-office growth is complete, the bank is open to acquiring new talent to support future growth. Q: How do you see the margin trending in the coming quarters, considering the deposit cost competition? A: Paul Egge expressed confidence in defending the margin, noting a strategic shift in funding composition. The bank aims to improve margins incrementally and reduce reliance on wholesale funds, focusing on core funding to maintain a strong margin profile. Q: What is the outlook for M&A activity, and how is Stellar Bancorp approaching potential partnerships? A: Robert Franklin mentioned that M&A discussions have increased, but the bank remains disciplined on pricing to avoid damaging the existing franchise. Stellar Bancorp is actively seeking partners to grow the balance sheet and the bank. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
5 minutes ago
- Yahoo
HCA Healthcare Inc (HCA) Q2 2025 Earnings Call Highlights: Strong EPS Growth and Strategic ...
Diluted Earnings Per Share: Increased 24% to $6.84. Revenue Growth: 6.4% increase driven by greater demand, improved payer mix, and consistent patient acuity levels. Equivalent Admissions: Increased 1.7% for the quarter and 2.3% for the year. Managed Care Equivalent Admissions: Grew 4% year-to-date. Medicare Growth: 3%, slightly below expectations. Adjusted EBITDA Margin: Improved by 30 basis points compared to the prior-year quarter. Adjusted EBITDA Growth: 8.4% over the prior-year quarter. Cash Flow from Operations: $4.2 billion in the quarter. Capital Expenditures: $1.2 billion in the second quarter. Share Repurchases: $2.5 billion in the second quarter. Dividends: $171 million in the second quarter. 2025 Revenue Guidance: Expected to range between $74 billion and $76 billion. 2025 Net Income Guidance: Expected to range between $6.11 billion and $6.48 billion. 2025 Adjusted EBITDA Guidance: Expected to range between $14.7 billion and $15.3 billion. 2025 Diluted EPS Guidance: Expected to range between $25.50 and $27. 2025 Capital Spending Guidance: Approximately $5 billion. Warning! GuruFocus has detected 4 Warning Signs with UVE. Release Date: July 25, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points HCA Healthcare Inc (NYSE:HCA) reported a strong financial performance for the second quarter of 2025, with a 24% increase in diluted earnings per share to $6.84. The company experienced solid revenue growth of 6.4%, driven by increased demand for services, improved payer mix, and consistent patient acuity levels. HCA Healthcare Inc (NYSE:HCA) improved quality outcomes, throughput measures in emergency rooms, and patient satisfaction during the quarter. The company increased its 2025 guidance, reflecting a positive demand environment and the effectiveness of strategic initiatives. HCA Healthcare Inc (NYSE:HCA) maintained a strong balance sheet and executed a balanced capital allocation strategy, including $4.2 billion in cash flow from operations and $2.5 billion in share repurchases. Negative Points Medicaid volumes were down slightly, and self-pay volumes were below expectations, representing the lowest reimbursing payers. The company anticipates some people will lose insurance coverage due to the expiration of enhanced premium tax credits, which could impact financial performance. HCA Healthcare Inc (NYSE:HCA) faces challenges from the One Big Beautiful Bill Act, which includes potential adverse impacts from Medicaid components and exchange provisions. The company experienced underperformance in a couple of markets, which offset some of the better performance in hurricane-affected markets. Supply expenses increased slightly as a percentage of revenue due to increased spending on cardiac-related devices. Q & A Highlights Q: Can you elaborate on the guidance update, particularly regarding the Tennessee DPP program and the modest tweak on admissions numbers? A: Michael Marks, CFO, explained that the $300 million increase in guidance is split equally between state supplemental payment programs, including the new Tennessee program, and better-than-expected performance in their portfolio. The Tennessee program is expected to start contributing cash in the latter half of the year. The admissions number was adjusted due to lower-than-expected Medicaid and self-pay volumes, but overall, the portfolio is performing well. Q: Could you provide more details on your resiliency programs, especially in light of the potential expiration of subsidies? A: Michael Marks stated that HCA is developing resiliency programs to offset potential adverse impacts from the expiration of enhanced premium tax credits (EPTCs). These efforts include benchmarking corporate departments, operational improvements, and leveraging automation and digital transformation. More details will be provided in the fourth-quarter earnings call. Q: What are you seeing in terms of commercial volume trends, and how might consumer confidence affect this? A: Michael Marks noted that managed care equivalent admissions are up 4% year-to-date, aligning with expectations. Exchange volumes are slightly better than expected, while traditional commercial volumes are slightly below. CEO Sam Hazen added that healthcare demand appears inelastic, and they haven't observed significant changes in consumer confidence affecting volumes. Q: How is HCA managing market share and local market dynamics, especially with high utilization rates reported by payers? A: CEO Sam Hazen highlighted sustained market share gains across service lines and markets. HCA is investing in network integrity and capacity to meet demand and achieve share gains. Despite some competitive dynamics, HCA remains agile and confident in its market positioning. Q: Can you provide insights into the impact of the One Big Beautiful Bill Act and the expiration of EPTCs on long-term guidance? A: Michael Marks stated that HCA's financial resiliency program should offset near-term impacts from the Act's exchange provisions. Long-term, HCA expects to manage impacts through phased reforms and potential supplemental payment approvals. The outcome of EPTCs is uncertain, but HCA is preparing resiliency plans to mitigate adverse effects. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data